Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib for Prostate Cancer

Phase-Based Progress Estimates
1
Effectiveness
1
Safety
Prostate Cancer+2 More
Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib - CombinationProduct
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial is testing the safety and effectiveness of a combination of 5 drugs for treating solid tumor cancers.

Eligible Conditions
  • Prostate Cancer
  • Prostate Cancer - Recurrent
  • Solid Tumors, Adult

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

2 Primary · 1 Secondary · Reporting Duration: Minimum of 3 months after start of treatment on each dose level

Week 16
Disease
Week 16
Change in Quality of Life (QOL) score
Month 3
Maximum Tolerated Dose (MTD) - Phase I

Trial Safety

Safety Progress

1 of 3

Trial Design

6 Treatment Groups

Dose level 2b
1 of 6
Dose level 1
1 of 6
Dose level 2a
1 of 6
Dose level 3a
1 of 6
Dose level 3b
1 of 6
Dose level 4
1 of 6
Experimental Treatment

76 Total Participants · 6 Treatment Groups

Primary Treatment: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib · No Placebo Group · Phase 1 & 2

Dose level 2b
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir · Intervention Types: CombinationProduct
Dose level 1
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus · Intervention Types: CombinationProduct
Dose level 2a
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus, Dasatanib · Intervention Types: CombinationProduct
Dose level 3a
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib · Intervention Types: CombinationProduct
Dose level 3b
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir · Intervention Types: CombinationProduct
Dose level 4
CombinationProduct
Experimental Group · 1 Intervention: Hydroxychloroquine, Metformin, Sirolimus, Nelfinavir, Dasatinib · Intervention Types: CombinationProduct

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: minimum of 3 months after start of treatment on each dose level

Who is running the clinical trial?

Medical University of South CarolinaLead Sponsor
833 Previous Clinical Trials
5,373,148 Total Patients Enrolled
18 Trials studying Prostate Cancer
764 Patients Enrolled for Prostate Cancer

Eligibility Criteria

Age 18+ · All Participants · 10 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 6th, 2021

Last Reviewed: October 19th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.